{"id":580338,"date":"2026-04-29T00:00:00","date_gmt":"2026-04-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0004-2026-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-current-treatment-current-treatment\/"},"modified":"2026-05-06T11:08:53","modified_gmt":"2026-05-06T11:08:53","slug":"cutron0004-2026-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-current-treatment-current-treatment","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0004-2026-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-current-treatment-current-treatment\/","title":{"rendered":"Non-Hodgkin&#8217;s Lymphoma and Chronic Lymphocytic Leukemia &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; B-Cell Non-Hodgkin&#8217;s Lymphoma (US)"},"content":{"rendered":"<p>Non-Hodgkin\u2019s lymphoma (<abbr data-abbreviation-entity=\"4909\" title=\"non-Hodgkin's lymphoma\">NHL<\/abbr>) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr>\u2014diffuse large B-cell lymphoma (<abbr title=\"diffuse large B-cell lymphoma\">DLBCL<\/abbr>) and mantle-cell lymphoma (<abbr title=\"mantle cell lymphoma\">MCL<\/abbr>)\u2014proceed directly to first-line treatment, whereas asymptomatic patients with indolent <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr>\u2014follicular lymphoma (<abbr title=\"follicular lymphoma\">FL<\/abbr>)\u2014are often managed with watchful waiting. Despite <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> subtype-specific considerations, rituximab-based regimens remain foundational across the disease spectrum. Recent regulatory approvals and label expansions are giving physicians an increasing array of treatment options, including Polivy (Roche\/Genentech\/Chugai) for previously untreated <abbr title=\"diffuse large B-cell lymphoma\">DLBCL<\/abbr>, Epkinly (Genmab \/ AbbVie) for relapsed\/refractory (<abbr title=\"relapsed\/refractory\">R\/R<\/abbr>) <abbr title=\"diffuse large B-cell lymphoma\">DLBCL<\/abbr> and <abbr title=\"follicular lymphoma\">FL<\/abbr>, Brukinsa (BeOne Medicines) and Monjuvi (Incyte) for <abbr title=\"relapsed\/refractory\">R\/R<\/abbr> <abbr title=\"follicular lymphoma\">FL<\/abbr>, Breyanzi (Bristol Myers Squibb) for <abbr title=\"relapsed\/refractory\">R\/R<\/abbr> <abbr title=\"follicular lymphoma\">FL<\/abbr> and <abbr title=\"mantle cell lymphoma\">MCL<\/abbr>, Adcetris (Pfizer\/Takeda) for <abbr title=\"relapsed\/refractory\">R\/R<\/abbr> <abbr title=\"diffuse large B-cell lymphoma\">DLBCL<\/abbr>, and Calquence (AstraZeneca) for previously untreated <abbr title=\"mantle cell lymphoma\">MCL<\/abbr>. These advances, alongside shifting prescribing patterns and increasing competition, are reshaping the treatment of <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr>.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the uptake and patient share of key therapies and regimens across all <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> subtypes?<\/li>\n<li>How do drug treatment rates vary across key <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> subtypes by therapy line?<\/li>\n<li>What are the key drivers and obstacles determining current prescribing patterns in <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr>?<\/li>\n<li>What are the clinical characteristics that physicians consider when prescribing <abbr title=\"chimeric antigen receptor\">CAR<\/abbr> T-cell therapies and bispecific antibodies for the various <abbr title=\"non-Hodgkin's lymphoma\">NHL<\/abbr> subtypes?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/li>\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<li>Analyze your brand\u2019s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<\/ul>\n<p><strong>Primary research: <\/strong>Survey of 100 U.S. hematologist-oncologists.<\/p>\n<p><strong>Key drugs covered<\/strong>: Adcetris, Breyanzi, Brukinsa, Calquence, Columvi, Epkinly, Gazyva, Imbruvica, Jaypirca, Kymriah, Lunsumio, Monjuvi, Polivy, rituximab, Tazverik, Tecartus, Xpovio, Yescarta, Zynlonta<\/p>\n","protected":false},"template":"","class_list":["post-580338","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hematological-malignancies","biopharma-therapy-areas-hematology","biopharma-therapy-areas-hodgkins-lymphoma","biopharma-therapy-areas-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/580338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/580338\/revisions"}],"predecessor-version":[{"id":580403,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/580338\/revisions\/580403"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=580338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}